<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543188</url>
  </required_header>
  <id_info>
    <org_study_id>C4471001</org_study_id>
    <nct_id>NCT04543188</nct_id>
  </id_info>
  <brief_title>A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement</brief_title>
  <official_title>A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human study to assess safety, tolerability, PK, and preliminary activity of&#xD;
      PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF&#xD;
      V600-mutated advanced solid tumor malignancies with and without brain involvement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1a - Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (approximately 21 days / 3 weeks)</time_frame>
    <description>DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a - Number of participants with treatment emergent adverse events (AEs)</measure>
    <time_frame>Baseline up to 30 days after last dose of study medication</time_frame>
    <description>AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a - Number of participants with clinically significant change from baseline in laboratory abnormalities</measure>
    <time_frame>Baseline up to follow up visit (30 days after last dose of study treatment)</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity, and timing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a - Number of dose interruptions, dose modifications, and discontinuations due to AEs</measure>
    <time_frame>Baseline through approximately 12 months</time_frame>
    <description>Incidence of dose interruptions, dose modifications, and discontinuations due to AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b - Overall response</measure>
    <time_frame>Baseline up to approximately 12 months</time_frame>
    <description>Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and intracranial response by modified RECIST version 1.1 (mRECIST v 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Maximum plasma concentration of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); End of Treatment (EOT)</time_frame>
    <description>Single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) pharmacokinetic (PK) parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Time to reach maximum plasma concentration of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Terminal half-life (t1/2) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose and multiple dose (assuming steady state is achieved and data permit) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose will be calculated as data permit PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Apparent oral clearance of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose (CL/F) and multiple dose (assuming steady state is achieved and as data permit; CLss/F) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Volume of distribution of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose (Vz/F) and multiple dose (assuming steady state is achieved and as data permit; Vss/F) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,T) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Multiple dose (assuming steady state is achieved) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Trough plasma concentration at steady state (Css,min) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Multiple dose (assuming steady state is achieved) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Accumulation ratio (Rac) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Multiple dose (assuming steady state is achieved and as data permit) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Overall response</measure>
    <time_frame>Baseline up to approximately 12 months</time_frame>
    <description>Response will be evaluated via radiographical tumor assessments by RECIST v1.1 and intracranial response by mRECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b - Number of patients with treatment emergent AEs</measure>
    <time_frame>Baseline up to 30 days after last dose of study medication</time_frame>
    <description>AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b - Number of participants with clinically significant change from baseline in laboratory abnormalities</measure>
    <time_frame>Baseline up to follow up visit (30 days after last dose of study treatment)</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity, and timing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b - Number of dose interruptions, dose modifications, and discontinuations due to AEs</measure>
    <time_frame>Baseline through approximately 12 months</time_frame>
    <description>Incidence of dose interruptions, dose modifications, and discontinuations due to AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum plasma concentration of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to reach maximum plasma concentration of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Terminal half-life (t1/2) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose and multiple dose (assuming steady state is achieved and data permit) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose will be calculated as data permit PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Apparent oral clearance of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose (CL/F) and multiple dose (assuming steady state is achieved and as data permit; CLss/F) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Volume of distribution of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Single dose (Vz/F) and multiple dose (assuming steady state is achieved and as data permit; Vss/F) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,T) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Multiple dose (assuming steady state is achieved) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Trough plasma concentration at steady state (Css,min) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Multiple dose (assuming steady state is achieved) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Accumulation ration (Rac) of PF-07284890 and binimetinib</measure>
    <time_frame>Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT</time_frame>
    <description>Multiple dose (assuming steady state is achieved and as data permit) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Disease Control Rate (DCR)</measure>
    <time_frame>Every 6 weeks from time of enrollment up to 1 year, then every 12 weeks thereafter</time_frame>
    <description>DCR is defined as the percent of participants with a confirmed complete response (CR), partial response (PR) or stable disease (SD) according to RECIST 1.1, at 6 weeks for both overall and intracranial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to measured progressive disease (up to 12 months)</time_frame>
    <description>The period from study entry until disease progression, death or date of last contact for both overall and intracranial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Overall Survival (OS)</measure>
    <time_frame>Baseline to date of death from any cause (up to 12 months)</time_frame>
    <description>Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Duration of Response (DoR)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 1 year, then every 12 weeks thereafter</time_frame>
    <description>Duration of response (DR) defined as time from start of first documented objective tumor response [Complete Response (CR) or Partial Response (PR)] to first documented objective tumor progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to Tumor Response (TTR)</measure>
    <time_frame>Every 6 weeks from the time of enrollment up to 12 months</time_frame>
    <description>TTR is defined as the time from first dose to first documentation of objective tumor response (CR or PR). For participants whose objective response (OR) proceeds from PR to CR, the onset of PR is taken as the onset of response. TTR will only be calculated for the subgroup of participants with a confirmed objective tumor response for both overall and intracranial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum plasma concentration (Cmax) of CYP34A probe substrate midazolam</measure>
    <time_frame>Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to reach maximum plasma concentration (Tmax) of CYP3A4 probe substrate midazolam</measure>
    <time_frame>Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of CYP3A4 probe substrate midazolam</measure>
    <time_frame>Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Terminal half-life (t1/2) of CYP3A4 probe substrate midazolam</measure>
    <time_frame>Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose)</time_frame>
    <description>PK parameter as data permit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of CYP3A4 probe substrate midazolam</measure>
    <time_frame>Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose)</time_frame>
    <description>PK parameter as data permit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Apparent oral clearance (CL/F) of CYP3A4 probe substrate midazolam</measure>
    <time_frame>Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose)</time_frame>
    <description>PK parameter as data permit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Volume of distribution (Vz/F) of CYP3A4 probe substrate midazolam</measure>
    <time_frame>Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose)</time_frame>
    <description>PK parameter as data permit</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Brain Neoplasms, Primary</condition>
  <condition>Brain Neoplasms</condition>
  <condition>Malignant Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-07284890 (Part A monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy dose escalation of PF-07284890</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07284890+binimetinib (Part A combo-therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination dose escalation of PF-07284890 + binimetinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Part B, Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or Non-Small Cell Lung Cancer (NSCLC), with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Part B, Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Part B, Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with asymptomatic brain involvement, and prior BRAF inhibitor utilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Part B, Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and prior BRAF inhibitor utilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Part B Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-Drug Interaction Substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07284890</intervention_name>
    <description>PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)</description>
    <arm_group_label>Drug-Drug Interaction Substudy</arm_group_label>
    <arm_group_label>Expansion Phase (Part B Cohort 5)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 2)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 3)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 4)</arm_group_label>
    <arm_group_label>PF-07284890 (Part A monotherapy)</arm_group_label>
    <arm_group_label>PF-07284890+binimetinib (Part A combo-therapy)</arm_group_label>
    <other_name>ARRY-461</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib</intervention_name>
    <description>Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily</description>
    <arm_group_label>Drug-Drug Interaction Substudy</arm_group_label>
    <arm_group_label>Expansion Phase (Part B Cohort 5)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 2)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 3)</arm_group_label>
    <arm_group_label>Expansion Phase (Part B, Cohort 4)</arm_group_label>
    <arm_group_label>PF-07284890+binimetinib (Part A combo-therapy)</arm_group_label>
    <other_name>Mektovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15</description>
    <arm_group_label>Drug-Drug Interaction Substudy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years at the time of consent&#xD;
&#xD;
          -  Histologically confirmed diagnosis of advanced/metastatic solid tumor including&#xD;
             primary brain tumor&#xD;
&#xD;
          -  Documented evidence of a BRAF V600 mutation in tumor tissue or blood&#xD;
&#xD;
          -  Confirmation of availability of adequate tumor tissue for submission to the&#xD;
             sponsor/central laboratory&#xD;
&#xD;
          -  Presence or absence of brain involvement unless specified below&#xD;
&#xD;
          -  Dose Expansion (Part B)&#xD;
&#xD;
               -  Cohort 1, 2, 3, 4: melanoma or NSCLC with at least 1 parenchymal brain lesion&#xD;
&#xD;
               -  Cohort 1,3: asymptomatic in the brain for at least 14 days prior to start of&#xD;
                  study treatment&#xD;
&#xD;
               -  Cohort 2,4: symptomatic in the brain within 14 days prior to the start of study&#xD;
                  treatment&#xD;
&#xD;
               -  Cohort 5: any solid tumor that does not meet requirements for Cohorts 1-4,&#xD;
                  history of or current leptomeningeal metastases.&#xD;
&#xD;
               -  Cohort 6 (DDI Sub-study): if brain involvement present, must be asymptomatic&#xD;
&#xD;
          -  Disease progression despite prior treatment and no acceptable alternative treatment&#xD;
             options available unless specified below&#xD;
&#xD;
          -  Dose Expansion (Part B)&#xD;
&#xD;
               -  Cohort 1, 2: No prior BRAF inhibitor in the metastatic setting or in the adjuvant&#xD;
                  setting within 6 months of study treatment&#xD;
&#xD;
               -  Cohort 3, 4: Required prior BRAF inhibitor in the metastatic setting or in the&#xD;
                  adjuvant setting within 6 months of treatment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastasis/primary brain tumor requiring immediate local intervention&#xD;
&#xD;
          -  History of or current leptomeningeal metastases&#xD;
&#xD;
          -  Any other active malignancy within 2 years prior to enrollment&#xD;
&#xD;
          -  Radiation therapy to visceral metastases within 14 days prior to study treatment. WBRT&#xD;
             within 28 days prior to study treatment.&#xD;
&#xD;
          -  Systemic anti-cancer therapy or small-molecular therapeutic(s) within 2 weeks prior to&#xD;
             start of study treatment; Antibody based agents within 4 weeks prior to start of study&#xD;
             treatment.&#xD;
&#xD;
          -  History or current evidence of RVO or current risk factors for RVO; History of retinal&#xD;
             degenerative disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope (City of Hope National Medical Center, City of Hope Medical Center)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope Investigational Drug Services (IDS)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Service</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University / Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston Inc (OCB)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - West County</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - North County</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University Infusion Center Pharmacy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - St Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Investigational Chemotherapy Services</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Pharmacy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4471001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proto-Oncogene Proteins B-raf</keyword>
  <keyword>Brain Neoplasms</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Neoplasms</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

